BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16432162)

  • 1. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
    Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
    Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
    Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
    Yang W; Barth RF; Wu G; Huo T; Tjarks W; Ciesielski M; Fenstermaker RA; Ross BD; Wikstrand CJ; Riley KJ; Binns PJ
    J Neurooncol; 2009 Dec; 95(3):355-365. PubMed ID: 19588228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.
    Barth RF; Wu G; Meisen WH; Nakkula RJ; Yang W; Huo T; Kellough DA; Kaumaya P; Turro C; Agius LM; Kaur B
    Onco Targets Ther; 2016; 9():2769-81. PubMed ID: 27274273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
    Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
    Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
    Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
    Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
    Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
    Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.
    Yang W; Barth RF; Leveille R; Adams DM; Ciesielski M; Fenstermaker RA; Capala J
    J Neurooncol; 2001 Oct; 55(1):19-28. PubMed ID: 11804279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas.
    Gibbs-Strauss SL; Samkoe KS; O'Hara JA; Davis SC; Hoopes PJ; Hasan T; Pogue BW
    Acad Radiol; 2010 Jan; 17(1):7-17. PubMed ID: 19796971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.